Active substance fedratinib
Holder BMS
Status Running
Indication treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis have been treated with ruxolitinib.
Public documents Approbation
  Approbation amendment
  Information for the patient
  Informed consent
Last update 08/08/2022


Last updated on 30/05/2023